Legend Biotech Corporation

NasdaqGS:LEGN Stock Report

Market Cap: US$9.2b

Legend Biotech Balance Sheet Health

Financial Health criteria checks 4/6

Legend Biotech has a total shareholder equity of $1.2B and total debt of $291.6M, which brings its debt-to-equity ratio to 25.2%. Its total assets and total liabilities are $1.8B and $639.2M respectively.

Key information

25.2%

Debt to equity ratio

US$291.56m

Debt

Interest coverage ration/a
CashUS$1.29b
EquityUS$1.16b
Total liabilitiesUS$639.18m
Total assetsUS$1.80b

Recent financial health updates

Recent updates

Legend Biotech: Entering Accelerated Growth Phase, Carvykti Positions Company For Valuation Expansion

Sep 18

Optimistic Investors Push Legend Biotech Corporation (NASDAQ:LEGN) Shares Up 26% But Growth Is Lacking

Aug 01
Optimistic Investors Push Legend Biotech Corporation (NASDAQ:LEGN) Shares Up 26% But Growth Is Lacking

Legend Biotech's Promising CAR-T Therapies Face Valuation And Cash Burn Challenges

Jul 30

Rock star Growth Puts Legend Biotech (NASDAQ:LEGN) In A Position To Use Debt

Jul 05
Rock star Growth Puts Legend Biotech (NASDAQ:LEGN) In A Position To Use Debt

Legend Biotech's Carvykti Faces Stiff Challenges Despite Advances

May 14

Some Shareholders Feeling Restless Over Legend Biotech Corporation's (NASDAQ:LEGN) P/S Ratio

May 13
Some Shareholders Feeling Restless Over Legend Biotech Corporation's (NASDAQ:LEGN) P/S Ratio

Legend Biotech: AdCom Documents Shed Light On Carvykti's Problems (Downgrade)

Mar 15

Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?

Mar 06
Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?

Legend Biotech: Solid Traction With Carvykti Rollout

Jan 29

Legend Biotech Corporation's (NASDAQ:LEGN) Share Price Not Quite Adding Up

Jan 16
Legend Biotech Corporation's (NASDAQ:LEGN) Share Price Not Quite Adding Up

Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?

Nov 09
Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?

Is Legend Biotech (NASDAQ:LEGN) Weighed On By Its Debt Load?

Apr 12
Is Legend Biotech (NASDAQ:LEGN) Weighed On By Its Debt Load?

An Intrinsic Calculation For Legend Biotech Corporation (NASDAQ:LEGN) Suggests It's 44% Undervalued

Dec 14
An Intrinsic Calculation For Legend Biotech Corporation (NASDAQ:LEGN) Suggests It's 44% Undervalued

Legend Biotech wins approval of Carvykti for multiple myeloma in Japan

Sep 27

Legend Biotech stock slides on proposed ADS offering

Jul 25

Legend Biotech ends Phase 1 trial for lymphoma candidate

Jul 07

News Flash: Analysts Just Made A Notable Upgrade To Their Legend Biotech Corporation (NASDAQ:LEGN) Forecasts

Jun 05
News Flash: Analysts Just Made A Notable Upgrade To Their Legend Biotech Corporation (NASDAQ:LEGN) Forecasts

Legend Biotech (NASDAQ:LEGN) Has Debt But No Earnings; Should You Worry?

May 14
Legend Biotech (NASDAQ:LEGN) Has Debt But No Earnings; Should You Worry?

Here's What Analysts Are Forecasting For Legend Biotech Corporation (NASDAQ:LEGN) After Its Full-Year Results

Mar 22
Here's What Analysts Are Forecasting For Legend Biotech Corporation (NASDAQ:LEGN) After Its Full-Year Results

Legend Biotech: Carvykti Approval Makes For A Buy Opportunity

Mar 04

Legend Biotech Corporation (NASDAQ:LEGN) Analysts Are More Bearish Than They Used To Be

Mar 03
Legend Biotech Corporation (NASDAQ:LEGN) Analysts Are More Bearish Than They Used To Be

Is Legend Biotech (NASDAQ:LEGN) Weighed On By Its Debt Load?

Dec 30
Is Legend Biotech (NASDAQ:LEGN) Weighed On By Its Debt Load?

Financial Position Analysis

Short Term Liabilities: LEGN's short term assets ($1.4B) exceed its short term liabilities ($294.3M).

Long Term Liabilities: LEGN's short term assets ($1.4B) exceed its long term liabilities ($344.9M).


Debt to Equity History and Analysis

Debt Level: LEGN has more cash than its total debt.

Reducing Debt: LEGN's debt to equity ratio has increased from 0.2% to 25.2% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: LEGN has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if LEGN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies